Glaxo Wellcome Receives FDA Approval of Relenza: A New Medicine to Treat Infl...
Relenza(R) (Zanamivir for Inhalation) Reduces the Duration of Flu RESEARCH TRIANGLE PARK, N.C., July 27 /PRNewswire/ - The approval of the first in a new class of medicines may mean influenza patients will be back on their feet sooner this winter. Glaxo Wellcome announced today that the U.S. Food
Publication: PR Newswire
Biota Sues GSK for Failure to Support its Influenza Drug Relenza(TM).
Biota Holdings Limited announced today that it had issued a writ in the Victorian Supreme Court, claiming breaches of contract and fiduciary duties by the worldwide GlaxoSmithKline (GSK) group for failing to promote and support Relenza(TM). The writ seeks unspecified damages for lost royalty
Publication: PR Newswire
Biota Announces New Drug Application for Relenza(TM) Filed with U.S. Food and...
Continues Global Market Application Strategy for Orally Inhaled Influenza Drug MELBOURNE, Australia, Oct. 28 /PRNewswire/ - Biota Holdings Limited announced today that its development partner, Glaxo Wellcome plc, has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration
Publication: PR Newswire
[0] US FDA APPROVES AUSTRALIAN FLU DRUG RELENZA FOR PAEDIATRIC USE.
MELBOURNE, May 30 Asia Pulse - Shares in Australian biotechnology company Biota Holdings (ASX:BTA) Ltd shot up 40 percent today after its anti-influenza drug Relenza was approved for paediatric use in the United States. Biota shares climbed $A1.11 to ($US0.63) to close at an intraday high of $3.86
Publication: AsiaPulse News
US FDA APPROVES AUSTRALIAN FLU DRUG RELENZA FOR PAEDIATRIC USE.
$all $aus $us $dru $reg $stx MELBOURNE, May 30 Asia Pulse - Shares in Australian biotechnology company Biota Holdings (ASX:BTA) Ltd shot up 40 percent today after its anti-influenza drug Relenza was approved for paediatric use in the United States. Biota shares climbed $A1.11 to ($US0.63) to close
Publication: AsiaPulse News
BIOTA ANNOUNCES TGA MARKETING CLEARANCE FOR RELENZA(R)
AAP General News (Australia) 03-27-1999 BIOTA ANNOUNCES TGA MARKETING CLEARANCE FOR RELENZA(R) BIOTA ANNOUNCES TGA MARKETING CLEARANCE FOR RELENZA(R) Melbourne, Australia, 26 March 1999/MediaNet International-AsiaNetBiotaHoldings Limited announces that Glaxo Wellcome Australia has received
Publication: AAP General News (Australia)
Biota Announces TGA Marketing Clearance for Relenza(R).
MELBOURNE, Australia, March 26 /PRNewswire/ - Biota Holdings Limited announces that Glaxo Wellcome Australia (NYSE: GLX) has received approval from the Therapeutic Goods Administration (TGA) of the Commonwealth Department of Health and Aged Care to market Relenza(R)(zanamivir for inhalation) for
Publication: PR Newswire
GSK Ready to Supply RELENZA(R) to Meet New CDC Interim Recommendations this F...
RESEARCH TRIANGLE PARK, N.C., Dec. 19 /PRNewswire/ - GlaxoSmithKline (GSK) is prepared to respond to public health needs for RELENZA(R) (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC). RELENZA is a
Publication: PR Newswire
Ample Supplies of Relenza Available as Flu Season Peaks.
RESEARCH TRIANGLE PARK, N.C., March 2 /PRNewswire-FirstCall/ - GlaxoSmithKline is prepared with ample supplies of the influenza antiviral medication RELENZA(R) (zanamivir) Inhalation Powder (httpwww.relenza.com/) to meet public health needs as the current influenza season peaks. According to newly
Publication: PR Newswire
French Stockpile of Relenza to increase from 200,00 Units to Nine Million Units
Biota (ASX: BTA) reported today that the French government has announced that it intends to increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years. Relenza normally sells for between AUD$25 and AUD$30 per unit in France, but no details are available
Publication: abnnewswire.net
Latest Relenza News:
